Competition and Regulation Issues in the Pharmaceutical Industry
401 Pages Posted: 30 Jul 2002
Date Written: February 6, 2001
This document (of 401 pages) comprises the proceedings of an OECD roundtable on competition and regulation issues in the pharmaceutical industry.
The pharmaceutical sector is a dynamic, research-intensive industry that is fundamentally influenced by a web of regulations designed to (a) promote research and innovation in the design and production of drugs, (b) protect consumers from potentially harmful effects of drugs, and (c) to control public and private expenditure on drugs. These objectives are sometimes in conflict and may require a balancing of the interests of producers and consumers. Since most consumers have some form of health insurance, their incentives to control their purchasers of pharmaceuticals or to purchase from the most efficient pharmacist are limited. Health insurers seek to control pharmaceutial expenditure through various policies such as co-payments, lists of approved drugs and maximum reimbursement levels for different drugs. If reimbursement levels for pharmacists are set at a national or regional level, incentives for entry by new pharmacists are excessive in certain locations, typically leading to restrictions on the establishment of new pharmacies. Well-thought out reform of this industry has the potential to reduce pharmaceutical expenditures while maintaining the quality of the drugs consumed.
This document includes a background paper by the Secretariat, submissions from 16 OECD countries and a summary of the oral discussion.
Keywords: Pharmaceuticals, patents, pharmacies, formularies, pharmaceutical mergers
JEL Classification: L40, L65
Suggested Citation: Suggested Citation